New Opportunities with DRIVe: ReBooT and RePAIR Amendments
The Biomedical Advanced Research and Development Authority’s (BARDA) Division of Research, Innovation & Ventures (DRIVe) has announced updates to its Easy Broad Agency Announcement (EZ-BAA) with Amendment #034. This amendment reopens and revises the ReBooT (AOI #22) program and pauses the RePAIR (AOI #24) initiative.
Overview of ReBooT (AOI #22)
The ReBooT program focuses on evaluating and supporting the development of antiviral therapeutics with efficacy against filoviruses such as Ebola, Sudan, and Marburg viruses. The initiative aims to address gaps in therapeutic evaluation caused by limited commercial incentives and logistical challenges associated with testing these candidates. ReBooT seeks proposals for antivirals that:
- Have progressed beyond Phase 1 clinical trials or are already licensed for other indications.
- Demonstrate mechanisms of action likely effective against filoviruses.
- Possess broad-spectrum activity against multiple virus species or genera.
- Are orally available and suitable for room-temperature storage.
Key objectives include conducting preclinical efficacy studies in animal models, exploring chemistry manufacturing and controls (CMC) activities, and ensuring the safety and viability of antiviral candidates. Preference will be given to products that can complement existing therapies or serve as effective monotherapies.
Pausing of RePAIR (AOI #24)
The RePAIR program, which focuses on regenerative medicine and injury repair, is currently paused as part of this amendment. While future updates may revisit this Area of Interest, interested vendors should remain informed for any upcoming announcements.
Submission Requirements and Key Dates
Interested vendors must meet specific submission requirements outlined in the EZ-BAA. Notably:
- Closing Date for Abstract Submissions (ReBooT): April 30, 2025, by 12:00 PM ET.
- Closing Date for Abstract Submissions (RePAIR): November 27, 2024, by 12:00 PM ET (pending further updates).
Abstracts must clearly define the project scope, methodologies, and desired outcomes. Respondents are encouraged to schedule pre-submission calls to refine their proposals and ensure alignment with program goals.
Funding and Award Information
BARDA anticipates making multiple awards for responsive proposals under the ReBooT program. Funding availability and award quantities will depend on scientific merit, program alignment, and budget constraints. Proposals should prioritize innovative approaches that meet the high standards of BARDA’s mission.
How to Apply
Submissions must adhere to the guidelines established under the EZ-BAA and its amendments. Respondents must be registered with SAM.gov to qualify for review. All submissions are subject to strict evaluation criteria, including the delivery of de-identified data and compliance with federal standards.
Advancing Antiviral Therapeutics and Medical Countermeasures
The ReBooT program represents a pivotal step in advancing antiviral research and development, addressing critical threats posed by filoviruses and other pandemic-potential RNA viruses. By supporting innovative therapeutics, BARDA’s DRIVe initiative continues to lead the way in safeguarding global health and preparing for future biological threats.
For organizations looking to contribute their expertise, EverGlade Consulting is here to help. Our team specializes in navigating federal funding opportunities and crafting compelling proposals. Contact us today to maximize your impact and drive innovation in antiviral research and beyond.